Compare Amgen, Inc. (AMGN) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Tyson Foods, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Tyson Foods, Inc. trades at $58.37 (market cap $20.36B). The key difference: Amgen, Inc. is far larger — about 9.6× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.53%). Which is the better fit depends on your goals.
| AMGN | TSN | |
|---|---|---|
Market Cap | $196.12B | $20.36B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $68.75 |
52-Week Low | $271.18 | $50.72 |
Enterprise Value | $241.41B | $27.95B |
Dividend Yield | 2.77% | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Tyson Foods (TSN) trades at $57.83, showing modest daily gains. The stock presents mixed signals with a bearish technical outlook but strong analyst support (50% buy ratings) and a consensus price target of $69.75. Recent earnings have beaten expectations in two of the last three quarters, while fundamentals show stable revenue near $54.4 billion but thin net margins of 0.81%. The company maintains dividend payments and is focusing on prepared foods growth.
The investment case balances value metrics like low P/S of 0.37 against profitability challenges. Upside potential exists if margin improvements materialize, but risks include volatile input costs and competitive pressures. The stock appears undervalued relative to analyst targets, suggesting cautious optimism for patient investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
